![Christopher Rex](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Rex
Plus aucun poste en cours
Profil
Christopher Rex is the founder of Afraxis, Inc., a company founded in 2007.
He held the title of Chief Scientific Officer from 2013 to 2021.
Dr. Rex also worked as a Program Director at T123 LLC from 2018 to 2021.
He obtained a doctorate degree from the University of California, Irvine in 2008 and an undergraduate degree from the University of California, Santa Barbara in 2002.
Anciens postes connus de Christopher Rex
| Sociétés | Poste | Fin |
|---|---|---|
Afraxis, Inc.
 Afraxis, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of fragile X syndrome and autism | Fondateur | 01/09/2021 |
T123 LLC
 T123 LLC Investment ManagersFinance T123 invests in companies located in the United States. The firm targets companies operating in the field of drug development industry. It provides financing for early stage capital requirements. | Directeur/Membre du Conseil | 01/04/2021 |
Formation de Christopher Rex
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
91
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Afraxis, Inc.
Afraxis, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of fragile X syndrome and autism | Health Technology |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Santa Barbara
 University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
T123 LLC
T123 LLC Investment ManagersFinance T123 invests in companies located in the United States. The firm targets companies operating in the field of drug development industry. It provides financing for early stage capital requirements. | Finance |
